|
|
|
|
|
非在研适应症- |
药物最高研发状态临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy With Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumor Malignancies
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.
0 项与 Zai Lab (Hong Kong) Ltd. 相关的专利(医药)